IL6 and liver disorder: Increasing evidence has shown that MSCs treatment alleviated various liver diseases through anti-inflammatory regulation.38,39 For example, MSCs from mice increased IL-6-dependent hepatocyte proliferation and reduced inflammatory TNF-α cytokine secretion.40 Our data indicated that BMSCs improved liver function and exerted anti-fibrosis effects in the BDL mice by alleviating inflammatory injury, reducing collagen fiber generation, and promoting tissue repair, which is similar to the findings of Li et al.41 This is a novel finding that may be valuable for the treatment of CLD.